Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (140)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (253)
  2. Department of Medicine (253)
  3. Solid Tumor Oncology Division (253)
  4. Survivorship Research (253)
  5. Epidemiology and Biostatistics (101)
  6. Biostatistics Service (87)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (6)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (79)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (80)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (253)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Journal Article

    Conlin, A.; Seidman, A.; Bach, A.; Lake, D.; Dickler, M.; D'Andrea, G.; Traina, T.; Danso, M.; Brufsky, A.; Saleh, M.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Determinants of outcome in elderly patients with positive sentinel lymph nodes
    Meeting Abstract

    Gemignani, M.; Karam, A.; Hsu, M.; Patil, S.; Stempel, M.; Traina, T.; Ho, A.; Cody, H. 3rd; Morrow, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
    Journal Article

    Morris, P. G.; Dickler, M.; Mcarthur, H. L.; Traina, T.; Sugarman, S.; Lin, N.; Moy, B.; Come, S.; Godfrey, L.; Nulsen, B.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer
    Meeting Abstract

    Traina, T. A.; Feigin, K.; Patil, S.; Yuan, J.; Dickler, M.; Andrea, G. D.; Bromberg, J.; Hudis, C.
    Annals of Oncology (2009)

    Fulltext@MSK | Save
  • A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Geneus, S.; Godfrey, L.; Norton, L.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • PIK3CA and AKT1 mutations are independent in invasive breast cancer
    Meeting Abstract

    Moynahan, M. E.; Heguy, A.; Drobnjak, M.; Traina, T.; Howard, J.; Patil, S.; Gerald, W.; Solit, D.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: No evidence of short-term changes in left ventricular ejection fraction
    Meeting Abstract

    Morris, P. G.; Dickler, M.; Mcarthur, H.; Traina, T.; Godfrey, L.; Steingart, R.; Rugo, H.; Lin, N.; Moy, B.; Come, S.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H.; Rugo, H.; Nulsen, B.; Traina, T.; Patil, S.; Zhou, Q.; Steingart, R.; Dang, C.; Park, J.; Moasser, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save